Kenalog

Piramal Pharma shares surged after a surprise return to quarterly profitability, 28% revenue growth and an upgraded FY2027 outlook. But high tax expenses, rising debt and a first-half loss raise a crucial question about how much of the operating recovery can reach shareholders.